Advertisement

Cancer vaccines

  • Malek M. Safa
  • Kenneth A. Foon
Chapter

Abstract

Immune approaches to the therapy of cancer have substantially evolved over recent years, from treating patients with nonspecific immune stimulants to a focus on the use of tumor-associated antigens (TAAs) either by passive immune therapy with antibodies targeted directly to tumor cells or by active immune therapy via vaccination with tumor cells, tumor cell lysates, peptides, carbohydrates, gene constructs encoding proteins, or anti-idiotype antibodies that mimic TAAs.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adluri S, Helling F, Ogata S et al. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTnKLH conjugates in colo-rectal carcinoma patients. Cancer Immunol Immunother 1995; 41: 185–92.Google Scholar
  2. 2.
    Allison JP, Hurwitz AA, Leach DR. Manipulation of co-stimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995; 7: 682–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Apostolopoulos V, Osinski C, McKenzie IFC. MUC1 cross-reactive Gala(1,3)Gal antibodies in humans switch immnune responses from cellular to humoral. Nat Med 1998; 4: 315–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Bakker A, Schreurs M, Tafazzul G. Identification of a novel peptide derived from the melanocyte-specific gpl00 antigen as the dominant epitope recognized by an HLA-A2.1- restricted anti-melanoma CTL line. Int J Cancer 1995; 62: 97–102.PubMedCrossRefGoogle Scholar
  5. 5.
    Bakker ABH, Schreurs MWJ, De Boer AJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179: 1005–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Barnd DL, Lan M, Metzgar R, Finn OJ. Specific MHCunrestricted recognition of tumor associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86: 7159–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Barth A, Hoon DSB, Foshag L et al. Polyvalent melanoma cell vaccine induced delayed type hypersensitivity and in vitro cellar immune response. Cancer Res 1995; 54: 3342–5.Google Scholar
  8. 8.
    Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CDIrestricted ab+ T cells. Nature (Lond) 1994; 372: 691–4.CrossRefGoogle Scholar
  9. 9.
    Belledegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA. Human tumor-infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 1989; 142: 4520–6.Google Scholar
  10. 10.
    Benchimol S, Fuks A, Jothy S, Beauchemia N, Shirota K, Stanners C. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Berd D, Kairys J, Dunto C, Mastrangelo MJ et al. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 1998; 25: 646–53.PubMedGoogle Scholar
  12. 12.
    Berd D, Maguire HC Jr, Mastrangelo MJ et al. Treatment of human melanoma with hapten-modified autologous vaccine. Ann NY Acad Sci 1993; 690: 147–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Berd D, Maguire HC Jr, McCue P et al. Treatment of metastatic melanoma with an autologous tumor cell vaccine: clinical and immunological results in 64 patients. J Clin Oncol 1990; 8: 1858–67.PubMedGoogle Scholar
  14. 14.
    Berd D, Maguire HC Jr, Mastrangelo MJ et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15: 2359–70.PubMedGoogle Scholar
  15. 15.
    Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Kohler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990; 145: 2758–65.PubMedGoogle Scholar
  16. 16.
    Bixby DL, Yannelli JR. CD80 expression in an HLA-A2 positive human non-small cell lung cancer cell line enhancesGoogle Scholar
  17. proliferation and cytotoxicity of A2 positive T-cells derived from normal donors and patients with non-small cell lung cancer. Int J Cancer 1998; 78: 685=94.Google Scholar
  18. 17.
    Boel P, Wildmann C, Sensi ML. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2: 167=75.Google Scholar
  19. 18.
    Bona CA. Idiotype vaccines: forgotten but not gone. Nat Med 1998; 4: 668=9.Google Scholar
  20. 19.
    Brichard V, Van Pel A, Wolfel T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 759= 64.Google Scholar
  21. 20.
    Brodsky FM, Guagliardi LE. The cell biology of antigen processing and presentation. Annu Rev Immunol 1991; 9: 707=44.Google Scholar
  22. 21.
    Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 1989; 44: 691=6.Google Scholar
  23. 22.
    Bystryn JC, Oratz R, Shapiro RL et al. Phase 3, double blind, trial of a shed polyvalent, melanoma vaccine in stage III melanoma. Proc Am Clin Oncol 1998; 17: 434a (abstract).Google Scholar
  24. 23.
    Bystryn JC, Oratz R, Henn M et al. Relationship between immune response to melanoma vaccine and clinical outcome in stage II malignant melanoma. Cancer 1992; 69: 1157=64.Google Scholar
  25. 24.
    Cahan LD, Irie RF, Singh R et al. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982; 79: 7629=33.Google Scholar
  26. 25.
    Castelli C, Storkus WJ, Maeurer MJ. Mass spectometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995;181:363=8.Google Scholar
  27. 26.
    Celluzi C, Mayodormo JI, Storkus WJ, Lotze MT, Fab LD Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996;183:283=7.Google Scholar
  28. 27.
    Chatterjee SK, Tripathi PK, Chakraborty M et al. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res 1998; 58: 1217=24.Google Scholar
  29. 28.
    Chen L, McGown P, Ashe S et al. Tumor immunogenicity determines the effect of B7 costimulation on T-cell mediated tumor immunity. J Exp Med 1994; 179: 523=32.Google Scholar
  30. 29.
    Chen T, Linsley PS, Hellstrom KE. Costimulation of T-cells for tumor immunity. Immunol Today 1993; 14: 483=6.Google Scholar
  31. 30.
    Cheresh DA, Varki AP, Varki NM et al. A monclonal antibody recognizes an O-acetylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem 1984; 259: 7453=9.Google Scholar
  32. 31.
    Conry RM, LoBuglio AF, Kantor J et al. Immunune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994; 54: 1164=8.Google Scholar
  33. 32.
    Coulie PG, Lehmann F, Lethe B. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995; 92: 7976=80.Google Scholar
  34. 33.
    Currie GA, Lejeune F, Hamilton-Fairley G. Immunization with irradiated tumor cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J 1971; 2: 305=10.Google Scholar
  35. 34.
    Denton GWL, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994; 57: 10=17.Google Scholar
  36. 35.
    Devine PL, Layton GT, Clark BA et al. Production of MUC1 and MUC2 mucins by human tumor cell lines. Biochem Biophys Res Commun 1991; 178: 593=9.Google Scholar
  37. 36.
    Ding L, Lalani E-N, Reddish M et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993; 36: 9=17.Google Scholar
  38. 37.
    Disis ML, Calenoff E, McLaughlin G. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16=20.Google Scholar
  39. 38.
    Disis NL, Gralow JR, Bernhard H. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J lmmunol 1996; 156: 3151=8.Google Scholar
  40. 39.
    Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766=74.Google Scholar
  41. 40.
    Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte=macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539=43.Google Scholar
  42. 41.
    Durrant LG, Buckley TJD, Denton GWL, Hardcastle JD, Sewell HF, Robins RA. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res 1994; 54: 4837=40.Google Scholar
  43. 42.
    Durrant LG, Doran M, Austin EB, Robins RA. Induction of cellular immune responses by a murine monoclonal antiidiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumors. Int J Cancer 1995; 61: 62=6.Google Scholar
  44. 43.
    Eder JP, Kantoff PW, Roper K et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6: 1632=8.Google Scholar
  45. 44.
    Euhus DM, Gupta RK, Morton DL et al. Induction of antibody to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989; 29: 247=54.Google Scholar
  46. 45.
    Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995;92:4773=7.Google Scholar
  47. 46.
    Falk K, Rotzchke O. Consensus motifs and peptide ligands of MHC class I molecules. Semin Immunol 1993; 5: 81=7.Google Scholar
  48. 47.
    Falk K, Rotzchke O, Stevanovic J. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.) 1991; 351: 290=4.Google Scholar
  49. 48.
    Fearon E, Pardoll D, Itaya T. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397=403.Google Scholar
  50. 49.
    Feltkamp MCW, Smits HL, Vierboom MPM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16- transformed cells. Eur J lmmunol 1993; 23: 2242=9.Google Scholar
  51. 50.
    Ferrone S, Temponi M, Natali PG et al. Selection and utilization of monoclonal antibody-defined melanoma associated antigens for immunoscintigraphy in patients with melanoma. SC Srivastava, ed. New York: Plenum Publishing Corp, 1988: 55=73.Google Scholar
  52. 51.
    Fisk B, Blevins TL, Wharton JT. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines. J Exp Med 1995; 181: 2109=17.Google Scholar
  53. 52.
    Fitch FW, Laneki DW, Gajewski TF. T-cell mediated immune regulation: help and suppression. In: Paul W, Nita E, eds. Fundamental Immunology, New York: Raven Press, 1993:733=61.Google Scholar
  54. 53.
    Flamand V et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24: 605=10.Google Scholar
  55. 54.
    Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res 1993; 53: 5386=94.Google Scholar
  56. 55.
    Foon KA, Bhattacharya-Chatterjee M. Idiotype vaccines in the clinic. Nat Med 1998; 4: 870.PubMedCrossRefGoogle Scholar
  57. 56.
    Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96: 334=42.Google Scholar
  58. 57.
    Foon KA, John WJ, Chakraborty M, Garrison J, Bard V, Bhattacharya-Chatterjee M. Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with an anti-idiotype (Id) monoclonal antibody that mimics carcinoembryonic antigen (CEA) with or without 5- fluorouracil. Proc Am Soc Clin Oncol 1998; 17: 435a.Google Scholar
  59. 58.
    Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997; 3: 1267=76.Google Scholar
  60. 59.
    Foon KA, Lutzky J, Baral RN et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglio side GD2. J Clin Oncol 2000; 8: 376=84.Google Scholar
  61. 60.
    Gendler SJ, Spicer AP, Lalani E-N et al. Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis 1991; 144: S42=7.Google Scholar
  62. 61.
    Gerner FR, Moore GE. Feasibility study of immunotherapy in patients with solid tumors. Cancer 1976; 38: 131=43.Google Scholar
  63. 62.
    Gilboa E, Lyerty HK. Specific active immunotherapy of cancer using genetically modified tumor vaccines. Biol Ther Cancer 1994; 6: 1=16.Google Scholar
  64. 63.
    Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000; 6: 1693=701.Google Scholar
  65. 64.
    Gjertsen MK, Buanes T, Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte=macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92: 441=50.Google Scholar
  66. 65.
    Govindaswami R, Meyers M, Livingston PO et al. Induction of antibodies against GD3 ganglioside in melanoma patients with GD3=lactone=KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 2000; 85: 659=66.Google Scholar
  67. 66.
    Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63: 298=304.Google Scholar
  68. 67.
    Grant EP, Rock KL. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J lmmunol 1992; 148: 13=18.Google Scholar
  69. 68.
    Gupta RK, Morton DL. Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst 1983; 70: 993=1004.Google Scholar
  70. 69.
    Hanna MG Jr, Pollack VA, Peters LC. Active-specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: effective treatment of BCG side effects with isoniazid. Cancer (Phila.) 1982; 49: 659=64.Google Scholar
  71. 70.
    Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994; 153: 4925=33.Google Scholar
  72. 71.
    Hareuveni M, Gautier C, Kieny M-P, Wreschner D, Chambon P, Lathe R. Vaccination against tumor cells expressingGoogle Scholar
  73. breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 1990; 87: 9498=502.Google Scholar
  74. 72.
    Harris JE, Ryan L, Hanna MG Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18: 148= 57.Google Scholar
  75. 73.
    Haurum JS, Arsequell G, Lellouch AC et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994; 180: 739=44.Google Scholar
  76. 74.
    Herlyn D, Harris D, Zaloudik J et al. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17–1A in animals and patients. J Immunother 1994; 15: 303=11.Google Scholar
  77. 75.
    Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 1992; 16: 251=60.Google Scholar
  78. 76.
    Hollingsworth MA, Strawhecker JM, Caffrey TC, Mack DR. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer 1994; 57: 198=203.Google Scholar
  79. 77.
    Hoon DSB, Yuzuki D, Hayashida M et al. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995; 154: 730=7.Google Scholar
  80. 78.
    Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11: 390=9.Google Scholar
  81. 79.
    Hoover HC Jr, Peters LC, Brandhorst JS. Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model. J Surg Res 1981; 30: 409=15.Google Scholar
  82. 80.
    Houghton AN, Lloyd KO. Stuck in the MUC on the long and winding road: antibodies that cross react with the tumor antigen MUC1 switch a cellular immune response to a humoral one with implications for the immunotherapy of cancer. Nat Med 1998; 4: 270=1.Google Scholar
  83. 81.
    Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16: 2913=20.Google Scholar
  84. 82.
    Hu X, Chakraborty NG, Sporn JR et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-3 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479=83.Google Scholar
  85. 83.
    Ikonopisov RL, Lewis MG, Hunter-Craig ID et al. Auto-immunization with irradiated tumor cells in human malignant melanoma. Br Med J 1970; 2: 752=4.Google Scholar
  86. 84.
    Itoh K, Platscousas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin-2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168: 1419=41.Google Scholar
  87. 85.
    Itzkowitz SH, Bloom EJ, Kokal WA. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer (Phila.) 1990; 66: 1960=6.Google Scholar
  88. 86.
    ltzkowitz S, Yuan M, Montgomery CK. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989; 49: 197=204.Google Scholar
  89. 87.
    Jaffee E, Dranoff G, Cohen L. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53: 2221=6.Google Scholar
  90. 88.
    Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic graulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145=6.Google Scholar
  91. 89.
    Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974; 125C: 373=89.Google Scholar
  92. 90.
    Jerome KR, Barnd DL, Bendt KM. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908=16.Google Scholar
  93. 91.
    Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune response induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992; 84: 1084=91.Google Scholar
  94. 92.
    Kantor J, Irvine K, Abrams S et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcino-embryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52: 6917=25.Google Scholar
  95. 93.
    Kast WM, Bronklhorst AM, DeWaal LP, Melief CJ. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. J Exp Med 1986;164:723=38.Google Scholar
  96. 94.
    Kast WM, Brandt RPM, Sidney J. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152: 3904=12.Google Scholar
  97. 95.
    Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991; 48: 900=7.Google Scholar
  98. 96.
    Kawakami Y, Eliyahu S, Delgado CH. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458=62.Google Scholar
  99. 97.
    Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961=8.Google Scholar
  100. 98.
    Kawakami Y, Eliyahu S, Sakaguchi K. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347=52.Google Scholar
  101. 99.
    Keene J, Forman J. Helper activity is required for the in vitro generation of cytotoxic T lymphocytes. J Exp Med 1982; 150:1134=42.Google Scholar
  102. 100.
    Key ME, Hanna MG Jr. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. Synergism between BCG and line 10 tumor cells in the induction of an inflammatory response. J Natl Cancer Inst 1981; 67: 853=61.Google Scholar
  103. 101.
    Kitamoura K, Livingston PO, Fortunato SR et al. Serological response patterns of melanoma patients immunized with a GM2 ganglioside vaccine. Proc Natl Acad Sci USA 1995; 92:2805=9.Google Scholar
  104. 102.
    Knight BC, Souberbielle BE, Rizzardi GP et al. Allogeneic murine melanoma cell vaccine; a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996; 6: 299=306.Google Scholar
  105. 103.
    Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107:477=84,.Google Scholar
  106. 104.
    Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Human immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res 1994; 54: 2856=60.Google Scholar
  107. 105.
    Kovacsovic-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (Washington DC) 1995; 267:243=5.Google Scholar
  108. 106.
    Krementz ET, Samuels MS, Wallace JH. Clinical experience in the immunotherapy of cancer. Surg Gynecol Obstet 1971; 133:209=17.Google Scholar
  109. 107.
    Kubo RT, Sett A, Grey HM. Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 1994; 152: 3913=24.Google Scholar
  110. 108.
    Laucius JF, Bodurtha AJ, Mastrangelo MJ et al. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer 1977;40:2091=3.Google Scholar
  111. 109.
    Leong SPL, Enders-Zohr P, Zhou YM et al. Recombinant human granulocyte macrophage=colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999; 22: 166=74.Google Scholar
  112. 110.
    Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol (Paris) 1973; 124:171=84.Google Scholar
  113. 111.
    Linehan DC, Goedegebuure PS, Peoples GE. Tumor specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995;155:4486=91.Google Scholar
  114. 112.
    Livingston PO, Adluri S, Helling F et al. Phase I trial of immunological adjuvant QS-21 with a GM2 gangliosideKLH conjugate vaccine in patients with malignant melanoma. Vaccine 1994; 12:1275=80.Google Scholar
  115. 113.
    Livingston PO, Natoli EJ, Calves MJ et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987; 84: 2911=15.Google Scholar
  116. 114.
    Livingston PO, Ritter F, Srivastava P et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1984; 49: 7045=50.Google Scholar
  117. 115.
    Livingston PO, Wong GYC, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1036=44.Google Scholar
  118. 116.
    Longenecker BM, Willan DJ, MacLean GD. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen=Friedenreich-like and Tn-like antigens on human cancers. J Natl Cancer Inst 1987;78:489=96.Google Scholar
  119. 117.
    MacLean GD, Reddish MA, Bowen-Yacshyn MB, Poppe-ma S, Longenecker BM. Active specific immunotherapy against adenocarcinomas. Cancer Invest 1994; 12: 46=56.Google Scholar
  120. 118.
    Magliani W, Polonelli L, Conti S et al. Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes. Nat Med 1998;4:705=9.Google Scholar
  121. 119.
    Marchand M, Van Baren N, Van der Bruggen P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219=30.Google Scholar
  122. 120.
    Marchand M, Weynants P, Rankin E. Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3. Int J Cancer 1995; 63: 883= 5.Google Scholar
  123. 121.
    Mayordomo JL, Zorina T, Storkus WJ. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995; 1: 1297=302.Google Scholar
  124. 122.
    McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC-2 antiidiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenecity when combined with adjuvant. Clin Cancer Res 1996; 2: 679=86.Google Scholar
  125. 123.
    McCarthy WH, Cotton G, Carlton A et al. Immunotherapy of malignant melanoma. A clinical trial. Cancer 1973; 32: 97=103.Google Scholar
  126. 124.
    McLaughlin JP, Abrams S, Kantor J et al. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte=macrophage colony-stimulat-Google Scholar
  127. ing factor (GM-CSF) induces tumor regression and long- lasting systemic immunity. J Immunother 1997; 20: 449=59.Google Scholar
  128. 125.
    McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996; 56: 2361=7.Google Scholar
  129. 126.
    Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000; 43: 88=100.Google Scholar
  130. 127.
    Miller K, Abeles G, Oratz R et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1998;75:495=502.Google Scholar
  131. 128.
    Mitchell MS, Harel W, Kan-Mitchell J et al. Active specific immnotherapy of melanoma with allogeneic cell lysates: rationale, results and possible mechanisms of action. Ann NY Acad Sci USA 1993; 690: 153=66.Google Scholar
  132. 129.
    Mitchell MS. Attempts to optimize specific immunotherapy for melanoma. Int Rev Immunol 1991; 7: 331=47.Google Scholar
  133. 130.
    Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Sem Onc 1998; 25: 623=35.Google Scholar
  134. 131.
    Mittelman A, Chen GZJ, Wong GY et al. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2–23: Modulation of the immunogenecity in patients with malignant melanoma. Clin Cancer Res 1995; 1: 705=13.Google Scholar
  135. 132.
    Mittelman A, Chen ZJ, Kageshita T et al. Active specific immunotherapy in patients with melanoma: a clinical trial with mouse anti-idiotype monoclonal antibodies elicited with syngeneic anti-high molecular-weight melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990; 86:2136=44.Google Scholar
  136. 133.
    Monaco J. A molecular model of MHC class-I-restricted antigen processing. Immunol Today 1992; 13: 173=9.Google Scholar
  137. 134.
    Moody DB, Reinhold BB, Guy MR et al. Structural requirements for glycolipid antigen recognition by CDlb-restricted T-cells. Science (Washington DC) 1997; 278: 283=6.Google Scholar
  138. 135.
    Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996; 46: 225=44.Google Scholar
  139. 136.
    Morton DL, Eilber FR, Holmes EC et al. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust NZ J Surg 1978; 48: 49=52.Google Scholar
  140. 137.
    Morton DL, Nizze A, Hoon DSB et al. Improved survival of advanced stage IV melanoma following active immunotherapy: correlation with immune responses to melanoma vaccine. Proc Am Soc Clin Oncol 1993; 12: 391 (abstract).Google Scholar
  141. 138.
    Mukherji B, Chakrababorty NG, Yamasaki S. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen-presenting cells. Proc Natl Acad Sci USA 1995; 92: 8078=82.Google Scholar
  142. 139.
    Muul LM, Spiess PJ, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in human bearing maligant melanoma. J Immunol 1987;138:989=95.Google Scholar
  143. 140.
    Nair S, Boczkowski D, Snyder D, Gilboa E. Antigen presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 1997; 27:589=97.Google Scholar
  144. 141.
    Nair S, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts. Cancer 1997; 70: 706=15.Google Scholar
  145. 142.
    Nelson WG, Simons JW, Mikhak B et al. Cancer cells engineered to secrete granulocyte=macrophage colony-stimulating factor using ex vivo gene transfer as vaccines forGoogle Scholar
  146. the treatment of genitourinary malignancies. Cancer Che-mother Pharmacol 2000; 46: S67=72.Google Scholar
  147. 143.
    Nestle NO, Alijagic S, Schadendorf D et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328=32.Google Scholar
  148. 144.
    Ockert D, Schirrmacher V, Beek N et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996; 2: 21=8.Google Scholar
  149. 145.
    Oikawa S, Inuzuka C, Kuroki M, Matsuoka Y, Kosaki G, Nakazato H. Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: homophilic and heterophilic adhesion. Biochem Biophys Res Commun 1989;164:39=45.Google Scholar
  150. 146.
    Ollila DW, Kelly MC, Gammon G et al. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 1998; 14: 328=36.Google Scholar
  151. 147.
    Osanto S. Vaccine trials for the clinician: prospects for tumor antigens. Oncologist 1997; 2: 284=99.Google Scholar
  152. 148.
    Parham P. Antigen processing. Transporters of delight. Nature (Lond.) 1990; 348: 674=5.Google Scholar
  153. 149.
    Parkhurst MR, Salgaller ML, Southwood S. Improved induction of melanoma reactive CTL with peptides from melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol 1995; 157: 2539=48.Google Scholar
  154. 150.
    Paxton RJ, Mooser G, Pande H, Lee TD, Shivley JE. Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin super-gene family. Proc Natl Acad Sci USA 1987; 84: 920=4.Google Scholar
  155. 151.
    Perez L, Hayes DF, Maimonis P, Abe M, O’Hara C, Kufe DW. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res 1992; 52: 2563=8.Google Scholar
  156. 152.
    Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee S. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 1997; 57: 728=34.Google Scholar
  157. 153.
    Peters LC, Hanna MG Jr. Active-specific immunotherapy of established micrometastasis: effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J Natl Cancer Inst 1980; 64: 1521=5.Google Scholar
  158. 154.
    Peters LC, Brandhorst JS, Hanna MG Jr. Preparation of immnunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979; 39: 1353=60.Google Scholar
  159. 155.
    Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone-marrow generated dendritic cells. J Immunol 1996; 156:2918=26.Google Scholar
  160. 156.
    Raulet D, Bevan M. Helper T cells for cytotoxic T lymphocytes need not be region restricted. J Exp Med 1982; 155: 1766=84.Google Scholar
  161. 157.
    Ravindranath MH, Morton DL, Irie RF et al. An epitope common to gangliosides 0-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy, Cancer Res 1989; 49: 3891=7.Google Scholar
  162. 158.
    Reece DE, Foon KA, Bhattacharya-Chatterjee M et al. Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant 2000; 26: 729=35.Google Scholar
  163. 159.
    Ressing ME, Van Driel W, Celis, E. Occasional memory CTL responses of patients with human papillomavirus type 16 positive cervical lesions against a human leukocyte antigen A*0201 restricted E7 encoded epitope. Cancer Res 1996;56:582=8.Google Scholar
  164. 160.
    Robins RA, Denton GWL, Hardcastle JD, Austin EB, Baldwin RW, Durmt LG. Antitumor immunune response and interleukin 2 production induced in colorectal cancerGoogle Scholar
  165. patients by immunization with human monoclonal antiidiotypic antibody. Cancer Res 1991; 51: 5425=9.Google Scholar
  166. 161.
    Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (Washington DC) 1990; 249: 918=21.Google Scholar
  167. 162.
    Rock KL, Rothstein L, Gamble S. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J lmmunol 1993; 150:438=46.Google Scholar
  168. 163.
    Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319: 1676=80.Google Scholar
  169. 164.
    Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321=7.Google Scholar
  170. 165.
    Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86:1159=66.Google Scholar
  171. 166.
    Rosenberg SA. Cell transfer therapy: clinical applications. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: Lippincott, 1995: 487= 506.Google Scholar
  172. 167.
    Rosenberg SA. Immunotherapy of patients with melanoma based on the genes encoding melanoma antigens. Proc Am Assoc Cancer Res 1996; 37: 642=3 (abstract).Google Scholar
  173. 168.
    Ruiz PJ, Wolkowicz R, Waisman A et al. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med 1998; 4: 710=12.Google Scholar
  174. 169.
    Samuel J, Noujaim AA, MacLean GD. Analysis of human tumor associated Thomsen=Friedenreich antigen. Cancer Res 1990; 50: 4801=8.Google Scholar
  175. 170.
    Sieling PA, Chatterjee D, Porcelli SA et al. CD1-restricted T-cell recognition of microbial lipoglycan antigens. Science (Washington DC) 1985; 269: 227=30.Google Scholar
  176. 171.
    Soiffer R, LynchT, Mihm M etal. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte=macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA1998; 95:13141=6.Google Scholar
  177. 172.
    Springer GF, Taylor CR, Howard DR. Tn, a carcinoma associated antigen, reacts with anti-Tn of normal human sera. Cancer (Phila) 1985; 55: 561=9.Google Scholar
  178. 173.
    Springer GF. T and Tn: general carcinoma antoantigens. Science (Washington DC) 1984; 224: 1198=206.Google Scholar
  179. 174.
    Staib L, Birebent B, Somasundaram R et al. Immunogenecity of recombinant GA733–2E antigen (CO17–1A, EGP, KS1–4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 2001; 92: 79=87.Google Scholar
  180. 175.
    Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271=96.Google Scholar
  181. 176.
    Tai T, Paulson JC, Cahan CD et al. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci USA 1983;80:5392=6.Google Scholar
  182. 177.
    Tao MH, Levy R. Idiotype/granulocyte=macrophage colony stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755=8.Google Scholar
  183. 178.
    Thompson J, Zimmerman W. The carcinoembryonic antigen gene family: structure, expressions, and evolution. Tumor Biol 1988; 9: 63=83.Google Scholar
  184. 179.
    Toes RE, Blom RJJ, Van Der Voort E et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996; 56: 3782=7.Google Scholar
  185. 180.
    Townsend A, Bodmer H. Antigen recognition by class I restricted T lymphocytes. Annu Rev Immunol 1989; 7: 601= 24.Google Scholar
  186. 181.
    Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington DC) 1993; 259: 368=70.Google Scholar
  187. 182.
    Traversari C, Van der Bruggen P, Luescher F. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T-lymphocytes directed against tumor antigen-MZ2-E. J Exp Med 1992; 176:1453=7.Google Scholar
  188. 183.
    Tsang KY, Zaremba S, Nieroda CA. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 982=90.Google Scholar
  189. 184.
    Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643=7.Google Scholar
  190. 185.
    Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990; 171: 1375=80.Google Scholar
  191. 186.
    Vitiello A, Ishioka G, Grey H. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest 1995; 95: 341=9.Google Scholar
  192. 187.
    Wallack MK, McNally KR, Leftheriotis E et al. A Southeastern cancer study group phase I/II trial with vaccinia melanoma oncolysates. Cancer 1986; 57: 649=55.Google Scholar
  193. 188.
    Wallack MK, McNally KR, Michaelides M et al. A phase I/ II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO). Am Surg 1986; 52:148=51.Google Scholar
  194. 189.
    Wallack MK, Scoggin SD, Sivanandham M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mt Sinai J Med 1992; 59: 227=33.Google Scholar
  195. 190.
    Wallack MK, Sivanandham M, Balch CM et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double blind multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187: 69=77.Google Scholar
  196. 191.
    Wallack MK, Steplewski Z, Koprowski H et al. A new approach in specific, active immunotherapy. Cancer 1977; 39: 560=4.Google Scholar
  197. 192.
    Wallack MK. A new approach in the immunotherapy of carcinoma of colon and rectum. J Surg Oncol 1980; 13: 29= 34.Google Scholar
  198. 193.
    Yang S, Darrow TL, Seigler HF. Generation of primary tumor specific cytotoxic lymphocytes from autologous and human lymphoyte antigen class I matched allogeneic peripheral blood lymphocytes by B7 gene modified melanoma cells. Cancer Res 1997; 57: 1561=8.Google Scholar
  199. 194.
    Yannelli JR, Hyatt C, Johnson S, Hwu P, Rosenberg SA. Characterization of human tumor cell lines with the cDNA encoding either tumor necrosis factor-a (TNF-A) or interleukin-2 (IL-2). J Immunol Methods 1993; 161: 77=90.Google Scholar
  200. 195.
    Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2= keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999;5:77=81.Google Scholar
  201. 196.
    Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996; 183: 7=11.Google Scholar
  202. 197.
    Zinkernagel R, Doherty P. MHC-restricted cytotoxic cell: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction-specificity, function and responsiveness. Adv Immunol 1979; 27: 51= 106.Google Scholar
  203. 198.
    Zitvogel L, Mayordomo JI, Tjandrawan T. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cell, B7 co-stimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87=97.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Malek M. Safa
  • Kenneth A. Foon

There are no affiliations available

Personalised recommendations